At a glance
ClinicalIndex Comparison Record- ✓B-cell non-Hodgkin's lymphoma with CD20+ expression
- ✓Evidence of engraftment following autologous peripheral blood stem cell transplant (ASCT)
- ✓ECOG performance status 0 to 1
- ✓Adequate renal function: creatinine < 2 mg/dL
- ✕Graft source from bone marrow (must be peripheral blood stem cells)
- ✕Prior non-response or disease progression with anti-CD20 therapy
- ✕Progressive disease after ASCT
- ✕Post-ASCT radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial Of C2B8 Monoclonal Antibody Following High Dose Therapy And Autografting In B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Rituximab 375 mg/m2 for Non-Hodgkin's Lymphoma and 5 related conditions. Completed, enrolled 35 participants across 1 site.
Detailed Summary
Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects. This study assesses autologous stem cell transplant (ASCT) supplemented with high-dose therapy increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas, as an alternative to the limitations of conventional therapy. Preliminary studies with rituximab in low grade lymphomas indicate a response rate of about 50% with very little toxicity. Rituximab is hypothesized to be a candidate for post-transplant therapy because the majority of malignant lymphomas express the CD20 antigen; rituximab has impressive independent anti-tumor activity; and the antibody has little toxicity outside of the acute administration.